Melanoma Treatment Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018 – 2026

The Melanoma Treatment Market: Overview

Melanoma is a kind of skin cancer that starts from melanocytes, which are pigment cells. It is produced by excessive UV light exposure, which causes sunburn, especially at high elevations. There are three types of melanoma: cutaneous, mucosal, and ocular. Cutaneous disorders impact the skin, mucosal disorders affect the mucous membrane in the mouth and nose passage, and ocular disorders affect the eye. Early identification of melanoma, on the other hand, aids treatment and increases survival rates. Melanoma is becoming more common and spreading to new body areas, according to a 2015 research by the American Academy of Dermatology. Treatment becomes much more difficult as it spreads to other sections of the body. Rare genetic disorders, such as xeroderma pigmentosum, increase the risk of developing cancer.

Several medications on the Melanoma Treatment Market have previously been approved by the FDA for the treatment of melanoma, and others are in the works. For the treatment of cutaneous melanoma, drugs such as Polynoma's seviprotimut-L, Amgen Inc.'s talimogene laherparepvec (T-VEC), and Roche and Genetech's zelboraf are being developed. AstraZeneca is developing selumetinib for the treatment of ocular melanoma. Bristol-Myers Squibb developed Yervoy, a monoclonal antibody medication, for the treatment of melanoma in 2011, and it was the first drug to earn FDA clearance. Opdivo and keytruda are immunotherapy medications that have been approved by the FDA and have offered new options in the melanoma treatment industry.

When chemotherapy fails to provide results, targeted therapy, such as BRAF inhibitors, is utilised. In compared to chemotherapy, targeted therapy has fewer adverse effects. According to the Cancer Research Institute, over 76,000 persons in the United States were diagnosed with melanoma in 2016. The melanoma treatment industry is predicted to rise due to the discovery of new medications and combination therapies with fewer side effects and higher survival rates.